Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Spectranetics (SPNC): Any info? -- Ignore unavailable to you. Want to Upgrade?

To: mahler_one who wrote (45)	7/24/2003 4:27:43 PM
From: mahler_one	Read Replies (1) \| Respond to of 60

Spectranetics (SPNC:Nasdaq - news - commentary - research - analysis): Private fund manager John Kuhn says this maker of devices used in minimally invasive cardiovascular-system procedures received Food and Drug Administration approval in 2001 to begin phase II trials for a procedure to treat patients with vascular disease potentially severe enough to warrant limb amputation. The "primary end point," or goal, is to salvage the limb. The last patient enrolled in April 2002 and the six-month follow-up was completed in October 2002. Data were submitted to the FDA in January 2003 and the company anticipates a final FDA decision in late 2003. Kuhn says the modestly profitable micro-cap seems well-run. Failure to win FDA approval for the procedure, he says, will cut the $3 stock in half; approval could send it to $10.